Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given their written consent to take part in the study
• People who agree to allow stored tissue samples from previous bone marrow biopsies to be used (exceptions may be possible with approval from the lead researcher)
• People between the ages of 60 and 75
• People who are reasonably independent in daily activities, as measured by a standard health performance scale (Karnofsky score of 70 or above)
• People with a confirmed diagnosis of one of the following blood cancers:
  • Acute myeloid leukemia (AML) — either a new diagnosis or one that developed from another condition, in first or later remission with certain risk features, or with signs of active disease detected through lab testing
  • Acute lymphoblastic leukemia (ALL) — either a new or secondary diagnosis with specific high-risk features, or with signs of active disease detected through lab testing
  • Myelodysplastic syndrome (MDS) — classified as higher-risk based on a standard scoring system
• People whose liver function blood tests are within acceptable ranges, tested within 30 days before starting treatment
• People whose kidney function is strong enough, based on testing within 30 days before starting treatment
• People whose heart is pumping at 50% or above, confirmed by a heart scan within 30 days before starting treatment
• People whose lung function tests show results at 50% or above of expected levels — or, if lung function tests cannot be done, whose blood oxygen level is above 92% on room air, tested within 30 days before starting treatment
• Women who could become pregnant must have a negative pregnancy test within 30 days before starting treatment
• People who can commit to using effective birth control or abstaining from heterosexual activity during the study and for at least 6 months after the last treatment dose
• People who have stopped intensive chemotherapy or radiation therapy at least 2 weeks before starting the study (certain low-dose or maintenance medications may be permitted closer to the start date — confirm with trial site)
• People who have a suitable stem cell donor available — this may be a fully matched sibling, a closely matched unrelated donor, or a half-matched (haploidentical) donor, assessed according to standard procedures and regulatory requirements

Who may not be able to join:

• People who have previously had an allogeneic (donor) stem cell transplant
• People who have had more than 3 prior rounds of intensive chemotherapy aimed at achieving remission
• People who are currently receiving another experimental treatment, or who have had intensive chemotherapy or radiation therapy within the 2 weeks before starting the study (some low-dose medications may still be permitted — confirm with trial site)
• People who have had allergic reactions to medications with a similar chemical makeup to the study drug
• People who have an uncontrolled or active infection (bacterial, viral, or fungal) at the time of enrolment
• People who currently have another active cancer, with the exception of certain low-risk cancers such as non-melanoma skin cancer, early-stage cervical cancer, or prostate cancer being monitored without treatment or previously treated with curative intent
• People whose overall health, mental health, or neurological condition may make it unsafe or too difficult to go through a transplant or to follow the treatment plan, in the opinion of the lead researcher
• People who are pregnant or breastfeeding
• People with any other condition that, in the researcher's judgment, would make participation unsafe
• People who, in the researcher's opinion, may be unable to follow all study procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.